St. Louis, MO (PRWEB) May 16, 2012
Veniti, a startup company focused on the treatment of venous disease, announced today it has added Dan Recinella as its VP of Research and Development and Karen Fraser as its Senior Director of Clinical Affairs. The new additions come as Veniti moves closer to its first product launch, a radio frequency generated steam ablation device, the Veni RF Plus™.
Recinella served as Vice President, Research and Development for AngioDynamics for the past eight years. In total, Recinella spent more than 22 years at AngioDynamics. He has a Bachelor’s Degree in Engineering from the University of Michigan and an MBA from State University of New York.
“We’re very excited to welcome Dan to our Veniti team,” said Sean Morris, CEO of Veniti. “His experience in research and development combined with his years in the vascular medical device industry makes him a perfect fit to help us take Veniti to the next level.”
Fraser joins Veniti as its Senior Director of Clinical Affairs, a title that she most recently held with MEDRAD Inc/Bayer Interventional in Minneapolis, Mn. There she was responsible for the development, management and implementation of MEDRAD’s Combination products’ clinical trials from inception through market approval. Working in the industry for the past 30 years, Fraser holds a Bachelor’s Degree in Nursing from Emory University and a Master’s Degree in Healthcare Policy Administration from Mercer University.
“Bringing Karen on board as our Senior Director of Clinical Affairs comes at a crucial time for us as we near the advent of our clinical trials,” said Morris. “Karen’s proven track record has everyone at Veniti excited about the experience she brings to the company. She offers deep relationships with physicians, scientists and clinical researchers in our space, and I’m confident that her skill set is exactly what Veniti needs to continue to grow.”
With now five team members in its office in California, and the addition of Recinella and Fraser to the staff, Veniti has filled 16 positions since its inception. Recently reported, Veniti has raised $15 million in its first round of funding. Investments have come from Chicago-based Baird Venture Partners, H&Q Healthcare Investors, H&Q Life Sciences Investors, New York-based Volcano Capital and local St. Louis based investors Prolog Ventures and the St. Louis Arch Angels. Veniti forecasts an additional seven to ten positions to be filled by the end of the year.
Veniti is a medical device company singularly focused on the venous disease space through the development and marketing of a range of premium innovative products that provide comprehensive treatment across the continuum of venous disease. Veniti products are all made in the USA. Research, development and manufacturing are conducted in Silicon Valley while the company’s leadership is headquartered in St. Louis. For more information, call 314.282.3753 or visit http://www.venitimedical.com.